La inequidad de sexo en la atención del cáncer de mama: una revisión general
DOI:
https://doi.org/10.31948/esrii.v9i2.4941Keywords:
cáncer de mama, desigualdades en salud, género y salud, inequidades en saludAbstract
El cáncer, un preocupante problema de salud pública, afecta a hombres y mujeres sin distinción de raza, cultura o condición social. Objetivo y método: este estudio cualitativo, con enfoque hermenéutico, se propone explorar la manera como han sido abordadas las desigualdades de género en la salud, centrándose en el cáncer de mama en el hombre. Destaca la importancia de incorporar perspectivas de género para reducir estas desigualdades en el ámbito de la salud. Resultados: los resultados revelan que el cáncer de mama en hombres parece estar relegado a un segundo plano, a pesar de su rareza, ya que la mayoría de los tratamientos se basan en esquemas utilizados en mujeres. Conclusión: se subraya la necesidad de integrar perspectivas de género en la investigación para abordar efectivamente las desigualdades de género, especialmente en el contexto del cáncer de mama en hombres. Se destaca la importancia de futuras investigaciones con un enfoque crítico en los problemas de salud de hombres y mujeres, reconociendo la relevancia de comprender cómo el género impacta la salud de las personas.
Author Biographies
Carlos Paz Gañan, Universidad de Carabobo
Doctorando en Salud Pública. Médico especialista en medicina oncológica y medicina interna, Universidad de Carabobo.
Alejandra Zuleta Medina, Escuela Normal Superior de Colombia
Ingeniera de Sistemas, Magíster en Educación y Doctora en Ciencias de la Educación, Universidad de Nariño. Profesora, Escuela Normal Superior de Pasto, Pasto. Departamento de Nariño. Colombia.
Evelin Escalona, Universidad de Carabobo
Doctora en Salud Pública, Profesora titular, Coordinadora del Doctorado en Salud Pública, Universidad de Carabobo
Aixa González De Paz, Universidad de Carabobo
Magíster en Salud Ocupacional e Higiene del Ambiente laboral, Universidad de Carabobo. Doctoranda en Salud Pública.
References
1. Wang J, Wu SG. Breast cancer: An overview of current therapeutic strategies, challenges, and perspectives. Breast Cancer. 2023 Oct 20; 15:721-730. https://doi.org/10.2147/BCTT.S432526 DOI: https://doi.org/10.2147/BCTT.S432526
2. International Agency for Research on Cancer [Internet]. IARC, Global Cancer Observatory, Globocan 2020. [citada el 13 de noviembre de 2023]. Disponible en: https://gco.iarc.fr/
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program [Internet]. SEER, Estimated New Cancer Cases and Deaths for 2021. [citada el 13 de noviembre de 2023]. Disponible en: https://seer.cancer.gov/
4. Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018 Feb 1;29(2):405-417. https://doi.org/10.1093/annonc/mdx651 DOI: https://doi.org/10.1093/annonc/mdx651
5. Leon-Ferre R, Giridhar K, Hieken, T, Mutter R, Couch F, Jimenez R et al. A contemporary review of male breast cancer: Current evidence and unanswered questions. Cancer Metastasis Rev. 2018 Dec;37(4):599-614. https://doi.org/10.1007/s10555-018-9761-x DOI: https://doi.org/10.1007/s10555-018-9761-x
6. World Health Organization [Internet]. WHO, Cáncer de mama 2023 [citada el 13 de noviembre de 2023]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer
7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. https://doi.org/10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
8. World Bank [Internet]. World Bank Open Data 2023 [citado el 13 de noviembre de 2023]. Disponible en: https://data.worldbank.org
9. United Nations [Internet]. UN, División de Población de las Naciones Unidas 2023 [citado el 13 de noviembre de 2023]. Disponible en: https://www.un.org/es/global-issues/population#
10. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal, A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019 Nov;69(6):438-451. https://doi.org/10.3322/caac.21583 DOI: https://doi.org/10.3322/caac.21583
11. Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. JAMA. 2020 Jul 28;324(4):369-380. https://doi.org/10.1001/jama.2020.9482 DOI: https://doi.org/10.1001/jama.2020.9482
12. Montazeri H, Manda A, Sidgal R, Chung C. Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories. Biomolecules. 2023 Aug 25;13(9):1306. https://doi.org/10.3390/biom13091306 DOI: https://doi.org/10.3390/biom13091306
13. Chuaychai A, Sriplung H. A rapid rise in hormone receptor-positive and HER2-positive breast cancer subtypes in Southern Thai women: A population-based study in Songkhla. PLoS One. 2022 Mar 28;17(3):e0265417. https://doi.org/10.1371/journal.pone.0265417 DOI: https://doi.org/10.1371/journal.pone.0265417
14. Kadys A, Gremke N, Schnetter L, Kostev K, Kalder M. Intercontinental comparison of women with breast cancer treated by oncologists in Europe, Asia, and Latin America: a retrospective study of 99,571 patients. J Cancer Res Clin Oncol. 2023 Aug;149(10):7319-7326. https://doi.org/10.1007/s00432-023-04681-7 DOI: https://doi.org/10.1007/s00432-023-04681-7
15. Dare A, Knapp G, Romanoff A, Olasehinde O, Famurewa O, Komolafe A, et al. High-burden Cancers in Middle-income Countries: A Review of Prevention and Early Detection Strategies Targeting At-risk Populations. Cancer Prev Res (Phila). 2021 Dec;14(12):1061-1074. https://doi.org/10.1158/1940-6207.CAPR-20-0571 DOI: https://doi.org/10.1158/1940-6207.CAPR-20-0571
16. Mishra G, Pimple S, Mittra I, Badwe R. Screening for breast cancer: Cost-effective solutions for low- & middle-income countries. Indian J Med Res. 2021 Aug;154(2):229-236. https://doi.org/10.4103/ijmr.IJMR_2635_20 DOI: https://doi.org/10.4103/ijmr.IJMR_2635_20
17. Ngo N, Nguyen H, Nguyen P, Vo T, Phung T, Pham A, et al. Health-related quality of life in breast cancer patients in low- and middle-income countries in Asia: a systematic review. Front Glob Womens Health. 2023 Jun 14; 4:1180383. https://doi.org/10.3389/fgwh.2023.1180383 DOI: https://doi.org/10.3389/fgwh.2023.1180383
18. Samaroo K, Hosein A, Olivier L, Ali J. Breast Cancer in the Caribbean. Cureus. 2021 Aug 9;13(8): e17042. https://doi.org/10.7759/cureus.17042 DOI: https://doi.org/10.7759/cureus.17042
19. Konduri S, Singh M, Bobustuc G, Rovin R, Kassam A. Epidemiology of male breast cancer. Breast. 2020 Dec; 54:8-14. doi: 10.1016/j.breast.2020.08.010.
https://doi.org/10.1016/j.breast.2020.08.010 DOI: https://doi.org/10.1016/j.breast.2020.08.010
20. Chen Z, Xu L, Shi W, Zeng F, Zhuo R, Hao X, et al. Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017. Breast Cancer Res Treat. 2020 Apr;180(2):481-490. https://doi.org/10.1007/s10549-020-05561-1 DOI: https://doi.org/10.1007/s10549-020-05561-1
21. Gooren L, T'Sjoen G. Endocrine treatment of aging transgender people. Rev Endocr Metab Disord. 2018 Sep;19(3):253-262. https://doi.org/10.1007/s11154-018-9449-0 DOI: https://doi.org/10.1007/s11154-018-9449-0
22. Safer J, Tangpricha V. Care of Transgender Persons. N Engl J Med. 2019 Dec 19;381(25):2451-2460. https://doi.org/10.1056/NEJMcp1903650 DOI: https://doi.org/10.1056/NEJMcp1903650
23. T'Sjoen G, Arcelus J, Gooren L, Klink D, Tangpricha V. Endocrinology of Transgender Medicine. Endocr Rev. 2019 Feb 1;40(1):97-117. https://doi.org/10.1210/er.2018-00011 DOI: https://doi.org/10.1210/er.2018-00011
24. Woods R, Salkowski L, Elezaby M, Burnside E, Strigel R, Fowler A. Image-based screening for men at high risk for breast cancer: Benefits and drawbacks. Clin Imaging. 2020 Mar;60(1):84-89. https://doi.org/10.1016/j.clinimag.2019.11.005 DOI: https://doi.org/10.1016/j.clinimag.2019.11.005
25. Jung H, Lim Y. Sonographic Features of Palpable Breast and Axillary Lesions in Adult Male Patients: A Pictorial Essay. J Korean Soc Radiol. 2022 Jul;83(4):830-845. https://doi.org/10.3348/jksr.2021.0122 DOI: https://doi.org/10.3348/jksr.2021.0122
26. Parikh U, Mausner E, Chhor C, Gao Y, Karrington I, Heller S. Breast Imaging in Transgender Patients: What the Radiologist Should Know. Radiographics. 2020 Jan-Feb;40(1):13-27. https://doi.org/10.1148/rg.2020190044 DOI: https://doi.org/10.1148/rg.2020190044
27. Davey M, Davey C, Bouz L, Kerin E, McFeetors C, Lowery A, et al. Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis. Breast. 2022 Aug; 64:41-46. https://doi.org/10.1016/j.breast.2022.04.009 DOI: https://doi.org/10.1016/j.breast.2022.04.009
28. Hassett M, Somerfield M, Baker E, Cardoso F, Kansal K, Kwait D, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol. 2020 Jun 1;38(16):1849-1863. https://doi.org/10.1200/JCO.19.03120 DOI: https://doi.org/10.1200/JCO.19.03120
29. Trapani D, Douillard J, Winer E, Burstein H, Carey L, Cortes J, et al. The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 Sep 4;113(9):1143-1155. https://doi.org/10.1093/jnci/djab011 DOI: https://doi.org/10.1093/jnci/djab011
30. Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg. 1994 Jan-Feb;18(1):63-9. https://doi.org/10.1007/BF00348193 DOI: https://doi.org/10.1007/BF00348193
31. Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, et al. Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review. Anticancer Res. 2018 Jan;38(1):23-31. https://doi.org/10.21873/anticanres.12187 DOI: https://doi.org/10.21873/anticanres.12187
32. Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Strittmatter H, et al. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 1;7(4):565-572. https://doi.org/10.1001/jamaoncol.2020.7442 DOI: https://doi.org/10.1001/jamaoncol.2020.7442
33. Kraus A, Yu-Kite M, Mardekian J, Cotter M, Kim S, Decembrino J, et al. Real-World Data of Palbociclib in Combination with Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men. Clin Pharmacol Ther. 2022 Jan;111(1):302-309. https://doi.org/10.1002/cpt.2454 DOI: https://doi.org/10.1002/cpt.2454
34. Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, et al. Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. Breast Cancer Res Treat. 2022 May;193(1):95-103. https://doi.org/10.1007/s10549-022-06543-1 DOI: https://doi.org/10.1007/s10549-022-06543-1
35. Benassai G, Miletti A, Calemma F, Furino E, De Palma G, Quarto G. Male breast cancer: an update. Ann Ital Chir. 2020; 91:359-365.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Excelsium Scientia: Revista Internacional de Investigación
This work is licensed under a Creative Commons Attribution 4.0 International License.
